Bioventix Market Cap ($1.24 Million)
Market Cap & Net Worth: Bioventix (BVXP)
Bioventix market cap. Bioventix (LSE:BVXP) has a market capitalization of $1.24 Million (GBX10.19 Billion) as of November 8, 2026. Listed on the LSE stock exchange, this UK-based company holds position #30505 globally and #768 in its home market, demonstrating a -3.70% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bioventix's stock price GBX1950.00 by its total outstanding shares 5224860 (5.22 Million). Also see BVXP cash flow metrics for how efficiently the company converts equity into cash flow.
Bioventix Market Cap History (2015–2026)
Bioventix market cap history from 2015 to 2026. Data shows growth from $555.86K to $1.24 Million (8.61% CAGR). Check BVXP stock price for real-time trading data and today's change.
Index Memberships
Bioventix is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE AIM All Share Index
FTAI
|
$990.01 Million | 0.13% | #133 of 722 |
Weight: Bioventix's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Bioventix Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bioventix's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of Bioventix to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.09x
Bioventix's market cap is 0.09 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.16x
Bioventix's market cap is 0.16 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $624.40K | $5.52 Million | $3.49 Million | 0.11x | 0.18x |
| 2017 | $1.19 Million | $7.25 Million | $4.92 Million | 0.16x | 0.24x |
| 2018 | $1.54 Million | $8.75 Million | $5.66 Million | 0.18x | 0.27x |
| 2019 | $1.72 Million | $9.29 Million | $5.86 Million | 0.19x | 0.29x |
| 2020 | $2.37 Million | $10.31 Million | $7.20 Million | 0.23x | 0.33x |
| 2021 | $1.91 Million | $10.93 Million | $6.73 Million | 0.17x | 0.28x |
| 2022 | $2.34 Million | $11.72 Million | $7.67 Million | 0.20x | 0.31x |
| 2023 | $2.63 Million | $12.82 Million | $8.37 Million | 0.21x | 0.31x |
| 2024 | $2.02 Million | $13.61 Million | $8.10 Million | 0.15x | 0.25x |
| 2025 | $1.21 Million | $13.12 Million | $7.58 Million | 0.09x | 0.16x |
Competitor Companies of BVXP by Market Capitalization
Companies near Bioventix in the global market cap rankings as of November 8, 2026. Also see Bioventix balance sheet assets for a full breakdown of the balance sheet.
Key companies related to Bioventix by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #177 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #363 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #403 globally with a market cap of $69.36 Billion USD ( AU$98.02 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #177 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $547.09 |
| #363 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $904.35 |
| #403 | CSL Ltd | AU:CSL | $69.36 Billion | AU$202.04 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $254.19 |
Market Capitalization of Bioventix (2015–2026)
Market capitalization of Bioventix from 2015 to today. Between 2015 and today, Bioventix's market cap moved from $555.86K to $ 1.24 Million, with a yearly change of 8.61%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX1.24 Million | +2.36% |
| 2025 | GBX1.21 Million | -40.00% |
| 2024 | GBX2.02 Million | -23.26% |
| 2023 | GBX2.63 Million | +12.23% |
| 2022 | GBX2.34 Million | +22.87% |
| 2021 | GBX1.91 Million | -19.36% |
| 2020 | GBX2.37 Million | +37.24% |
| 2019 | GBX1.72 Million | +11.86% |
| 2018 | GBX1.54 Million | +29.21% |
| 2017 | GBX1.19 Million | +90.98% |
| 2016 | GBX624.40K | +12.33% |
| 2015 | GBX555.86K | -- |
End of Day Market Cap According to Different Sources
On Nov 7th, 2026 the market cap of Bioventix was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.24 Million USD |
| MoneyControl | $1.24 Million USD |
| MarketWatch | $1.24 Million USD |
| marketcap.company | $1.24 Million USD |
| Reuters | $1.24 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Bioventix
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. It offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; Pyrene 1-hydroxypyrene glucuronide (HOP-G) ELISA kit to monitor human exposure to industrial pollutants; and Pyrene (HOP-G) lateral flo… Read more